Tenpoint Therapeutics won FDA approval for Yuvezzi, a first‑in‑class combination eye drop (carbachol + brimonidine) for presbyopia, and closed up to $235 million in financing to support commercialization. The approval positions Tenpoint as a new entrant in the competitive topical presbyopia market and follows the company’s late‑stage regulatory efforts. Tenpoint said the financing package comprises Series B equity and a $150 million term loan facility; the company intends to use proceeds to launch and market Yuvezzi. The product differentiates itself by combining two mechanisms in a single formulation, targeting near‑vision improvement with a dual‑agent approach. Regulatory clearance and fresh capital aim to speed market entry against incumbents (AbbVie, Orasis, Lenz) and will test demand for pharmacologic alternatives to reading glasses. Commercial execution, patient adoption, and pricing will determine uptake in a category where consumer behavior and ophthalmologist prescribing patterns matter. Observers will track rollout metrics and early real‑world tolerability; the deal also demonstrates investor willingness to fund later‑stage ophthalmology launches tied to clear regulatory outcomes.